{"id":"ceftriaxone-oxacillin","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Phlebitis at injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftriaxone is a third-generation cephalosporin that inhibits cross-linking of peptidoglycan in bacterial cell walls. Oxacillin is a beta-lactamase-resistant penicillin effective against staphylococci. Together, they provide synergistic coverage against a wide range of aerobic and anaerobic bacteria, particularly useful in serious infections where broad coverage is needed.","oneSentence":"This combination of two beta-lactam antibiotics inhibits bacterial cell wall synthesis through inhibition of penicillin-binding proteins, providing broad-spectrum coverage against gram-positive and gram-negative bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:39:58.702Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections including meningitis, endocarditis, and sepsis"},{"name":"Hospital-acquired and community-acquired infections with mixed gram-positive and gram-negative pathogens"}]},"trialDetails":[{"nctId":"NCT04563325","phase":"PHASE4","title":"Oral-only Antibiotics for Bone and Joint Infections in Children","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2020-09-15","conditions":"Osteomyelitis, Septic Arthritis, Bone Infection","enrollment":180},{"nctId":"NCT05929599","phase":"NA","title":"Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Children's Hospital, Vietnam","startDate":"2023-07-05","conditions":"Acute Respiratory Tract Infections, Pneumonia, Respiratory Syncytial Virus (RSV)","enrollment":120},{"nctId":"NCT06616168","phase":"PHASE1","title":"Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens","status":"ACTIVE_NOT_RECRUITING","sponsor":"Danylo Halytsky Lviv National Medical University","startDate":"2023-09-01","conditions":"Bacterial Vaginosis","enrollment":200},{"nctId":"NCT06454643","phase":"NA","title":"Gentamicin in Cardiac Surgery","status":"COMPLETED","sponsor":"Al-Rasheed University College","startDate":"2020-01-01","conditions":"Cardiac Infection","enrollment":50},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":"Endocarditis","enrollment":20},{"nctId":"NCT02334124","phase":"NA","title":"Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2015-01","conditions":"Cellulitis","enrollment":190},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04141787","phase":"PHASE4","title":"Ceftriaxone as Home IV for Staph Infections","status":"UNKNOWN","sponsor":"Vancouver Island Health Authority","startDate":"2019-07-11","conditions":"Staphylococcal Infections, Osteomyelitis, CNS Infection","enrollment":310},{"nctId":"NCT01756924","phase":"PHASE2","title":"Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection","status":"TERMINATED","sponsor":"Arrevus Inc.","startDate":"2012-12","conditions":"Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers","enrollment":14},{"nctId":"NCT01166932","phase":"PHASE4","title":"Comparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumonia","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2005-04","conditions":"Community-Acquired Pneumonia","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":288,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ceftriaxone/oxacillin","genericName":"ceftriaxone/oxacillin","companyName":"UPECLIN HC FM Botucatu Unesp","companyId":"upeclin-hc-fm-botucatu-unesp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of two beta-lactam antibiotics inhibits bacterial cell wall synthesis through inhibition of penicillin-binding proteins, providing broad-spectrum coverage against gram-positive and gram-negative bacteria. Used for Serious bacterial infections including meningitis, endocarditis, and sepsis, Hospital-acquired and community-acquired infections with mixed gram-positive and gram-negative pathogens.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}